Inhaled Nitric Oxide Delivery Systems Market Analysis

  • Report ID: 5855
  • Published Date: Apr 23, 2025
  • Report Format: PDF, PPT

Inhaled Nitric Oxide Delivery Systems Segmentation

Type (Pediatric, Adult)

Based on type, pediatric segment in the inhaled nitric oxide delivery systems market is anticipated to hold 80% of the revenue share by 2037.  In the U.S. alone, nearly 25,000 to 30,000 neonatal HRF cases are reported annually and nearly 50% are cured using INO therapy. For 72 to 96 hours, the average cost of this treatment is almost 150 USD per hour, which represents a total of 97,000 to 130,000 USD per patient. Therefore, a favourable reimbursement policy has been established by the government of many countries in order to cover high healthcare costs and thus improve adoption of INO therapy for newborn children. In most adult infectious diseases, inhaled nitric oxide should be administered at high concentrations and due to a lack of clinical evidence this treatment has been less commonly used in adults. Nitric oxide inhalation is used to treat respiratory conditions in babies and newborns. These illnesses may include persistent pulmonary hypertension of the newborn, a severe condition that arises when a newborn's blood pressure in the lungs is abnormally high, and bronchopulmonary dysplasia, a chronic lung abnormality that can manifest in premature newborns. Treating these issues in infants and young children has shown promise when nitric oxide is inhaled. Therefore, the pediatric population has a significant need for inhaled nitric oxide delivery devices.

End User (Ambulatory Center, Hospitals)

Based on end user, the hospital segment in the inhaled nitric oxide delivery systems market is anticipated to hold 60% of the revenue share during the forecast period. This growth can be attributed to ease of delivery, the ability to liquidate when setting up INOs and monitoring systemss, a high number of personnel who monitor device operation as well as an emergency department. In the world, ARF mortality rates are around 30%. Life support and intensive care, like in the Intensive Care Unit of a hospital, is therefore essential for these patients. This segment is being driven by an increase in hospital admissions.

Our in-depth analysis of the global market includes the following segments:

          Type

  • Pediatric
  • Adult

          Application

  • Hypoxemic Respiratory Failure Treatment
  • Acute Vasoreactivity Testing
  • Pulmonary Hypertension Treatment

          End User

  • Ambulatory Center
  •  Hospitals

          Product

  • Disposables
  • Systems

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

Inhaled Nitric Oxide Delivery Systems Market in 2025 is assessed at USD 382.26 million.

The global market size was worth more than USD 368.41 million in 2024 and is poised to witness a CAGR of over 4.7%, crossing USD 669.33 million revenue by 2037.

North America is projected to reach USD 234.27 million by 2037, fueled by COPD prevalence and growing INO therapy adoption.

The major players in the market include Beyond Air, SLE, NU MED, Bellerophon Therapeutics, Mallinckrodt Pharmaceuticals, Air Liquide Healthcare, and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos